Skip to main content
DNTH logo

DNTH · Dianthus Therapeutics, Inc. /DE/ · Metrics

Track DNTH — free
$78.75 +4.21 (+5.65%)
Market Cap
$4.40B
Shares
55.93M
Volume · Oct 20 1.87M Avg daily vol (3M) 822.38K

DNTH metrics

67 of 122 screener metrics currently available.

Open in screener

Market overview

2 metrics
Share price
$78.75
Market cap
$4.40B

Price action

20 metrics
Price change (1W)
-8.6%
Price change (30D)
-22.7%
Price change (3M)
-26.2%
Price change (6M)
-18.9%
Price change (YTD)
+80.9%
Price change (1Y)
+109.1%
Trailing year
Price change (5Y)
-27.0%
52-week high
$115.96
52-week low
$32.92
Change from 52-week high
-35.7%
Change from 52-week low
+126.4%
Annualized volatility
61.0%
Annualized volatility (3M)
43.1%
Beta
1.0
RSI (14D)
23.0
Price vs SMA 50
-24.4%
Price vs SMA 200
-10.4%
Avg volume (3M)
806,571
Relative volume
1.2
Average dollar volume
$79.68M

Company

3 metrics
Sector
Healthcare
Industry
Biotechnology
Shares outstanding
55.93M

Valuation

12 metrics
P / E (TTM)
—
Trailing earnings
PEG ratio
—
EV / revenue
—
EV / EBITDA
—
EV / EBIT
—
P / sales
2,047.8×
reciprocal yield 0.0%
P / book
3.6
reciprocal yield 28.1%
FCF yield
—
TTM · current market cap
Buyback yield
—
P / FCF
—
P / operating cash flow
—
Earnings yield
-4.6%

Historical valuation

8 metrics
P / E historical average (3Y)
—
P / E historical average (5Y)
—
EV / revenue historical average (3Y)
764.5×
reciprocal yield 0.1%
EV / revenue historical average (5Y)
764.5×
reciprocal yield 0.1%
EV / EBIT historical average (3Y)
—
EV / EBIT historical average (5Y)
—
EV / EBITDA historical average (3Y)
—
EV / EBITDA historical average (5Y)
—

Dividends & buybacks

7 metrics
Dividend yield
—
Trailing 12 months
Payout ratio
—
Shareholder yield
—
Dividend / share (TTM)
—
Dividend growth YoY
—
Dividend growth streak
—
Last ex-dividend
—

Earnings calendar

2 metrics
Next earnings
—
Last earnings
2026-03-09

Profitability

9 metrics
Gross margin
—
Operating margin
-8,739.3%
Trailing 12 months
Net margin
-7,973.3%
Gross profit (TTM)
—
Operating profit (TTM)
−$217.84M
Net income (TTM)
−$192.25M
Trailing 12 months
Diluted EPS (TTM)
$-4.25
FCF margin
—
Effective tax rate
—

Per share

11 metrics
Revenue per diluted share (TTM)
—
Gross profit per diluted share (TTM)
—
Operating profit per diluted share (TTM)
—
EBITDA per diluted share (TTM)
—
Net income per diluted share (TTM)
—
Operating cash flow per diluted share (TTM)
—
Free cash flow per diluted share (TTM)
—
Capital expenditures per diluted share (TTM)
—
R&D per diluted share (TTM)
—
Stock compensation per diluted share (TTM)
—
Book value per share
$11.42

Growth

11 metrics
Revenue growth YoY
-78.6%
Year over year
Net income growth YoY
—
Revenue (TTM)
$2.04M
Trailing 12 months
EPS growth YoY
—
Shares change YoY
+56.4%
Year over year · more shares
Revenue CAGR (3Y)
-31.8%
Revenue CAGR (5Y)
—
EPS CAGR (3Y)
—
EPS CAGR (5Y)
—
FCF CAGR (3Y)
—
FCF CAGR (5Y)
—

Quality

14 metrics
Return on equity
-16.4%
Return on assets
-15.8%
Debt / equity
0.0
Current ratio
26.1
EBITDA (TTM)
−$5.89M
Free cash flow (TTM)
—
Quick ratio
26.1
Interest coverage
—
Net debt / EBITDA
—
Return on invested capital
—
Trailing 12 months
Net cash
$886.81M
Latest balance sheet
Cash & equivalents
$110.55M
Total assets
$1.21B
Total debt
$0

Cash flow & spend

7 metrics
Operating cash flow (TTM)
−$155.38M
Capital expenditures (TTM)
$403,000
R&D (TTM)
$175.60M
SG&A (TTM)
—
Stock compensation (TTM)
$34.27M
R&D / revenue
—
Stock compensation / revenue
—

Ownership (13F)

9 metrics
13F filers
272
13F filer change QoQ
+29
Institutional ownership
118.4%
Conviction holders (share of 13F filers)
3.7%
Crowding (high-turnover and private-fund holders)
—
Private-fund adviser ownership
—
Active holders' share change QoQ
+2.0%
Holder tenure
7.2
Price vs estimated holder cost
+110.5%

Ownership (registered funds)

1 metrics
Index-fund ownership
13.2%

Short interest

3 metrics
Short interest
16.3%
Latest settlement · 8.3 days to cover
Days to cover
8.3d
Short-squeeze score
71 / 100

Insider activity

2 metrics
Net insider buying (90D)
−$26.12M
Insider-sentiment score
—

Risk flags

1 metrics
Going concern
—
Key facts CIK 1690585 CUSIP 252828108 13F (30d) 12 filings 12 filers Visit website Investor relations